EGFR and non-small cell lung carcinoma: A first important finding is that the setting of stage IV disease, de novo vs. secondary, itself is not associated with survival of EGFR+ NSCLC patients from the time of stage IV diagnosis: PFS under TKI or chemotherapy, and OS were similar among the two patient groups (Table 1).